heparitin-sulfate and Leukemia--Erythroblastic--Acute

Heparanase (HPSE) is an endo-β-D-glucuronidase that cleaves heparan sulfate and hence participates in remodeling of the extracellular matrix, leading to release of cytokines that are immobilized by binding to heparan sulfate proteoglycans (HSPGs), and consequently activating signaling pathways. This function of HPSE is correlated to its expression level that is normally very low in majority of the tissues. Exceptionally, human platelets express high level of HPSE, suggesting a unique physiological role in this cell. Using K562 cell line, we found a progressive increase of HPSE during the megakaryocytic differentiation. Analysis of a series of megakaryocytic differentiation-related heparin-binding proteins (HBPs) in the cell culture medium revealed an exclusive positive correlation between the level of interleukin 6 (IL-6) and HPSE expression. IL-6 modulated megakaryocytic differentiation through activation of STAT3. Further, we demonstrated that overexpression of HPSE potentiates megakaryocytic differentiation, whereas elimination of HPSE led to a delayed differentiation. This function of HPSE is associated with its activity, as overexpression of inactive HPSE had no effect on IL-6 production and megakaryocytic differentiation. The role of HPSE is further supported by the observation in an umbilical cord blood CD34+ cells megakaryocytic differentiation model. Our data propose a novel role for HPSE in platelets production by a HPSE/IL-6/STAT3 positive feedback loop that specifically regulates megakaryocytes maturation.

Topics: Carcinogenesis; Cell Differentiation; Extracellular Matrix; Feedback, Physiological; Fetal Blood; Glucuronidase; Heparitin Sulfate; Humans; Interleukin-6; K562 Cells; Leukemia, Erythroblastic, Acute; Megakaryocytes; Signal Transduction; STAT3 Transcription Factor; Tetradecanoylphorbol Acetate

We have previously reported that platelet factor 4 (PF4) inhibits human erythroleukemic (HEL) cell growth in a dose-dependent fashion in vitro and that PF4 binds to HEL cells in a specific, saturable, and concentration-dependent manner. In this article we demonstrate that the binding of PF4 on HEL cells and its inhibitory effect on HEL cell growth were mediated by heparan sulfate. We found that binding of iodine 125-labeled PF4 to HEL cells was inhibited by heparin, heparan sulfate, and dermatan sulfate and to a smaller extent by chondroitin sulfate. Ninety percent of 125I-labeled PF4 bound to HEL cells was released by cells after exposure to heparin and heparan sulfate. Treatment of cells with heparitinase and heparinase induced a decrease in the binding of 125I-labeled PF4 to cells. Binding of 125I-labeled PF4 was partially inhibited by the presence of increasing concentrations of protamine sulfate and basic fibroblast growth factor. To test whether PF4 bound to cell surface proteoglycans, proteoglycan synthesis was inhibited by using 4-methylumbelliferyl-beta-D-xyloside. The binding of 125I-labeled PF4 on treated cells was decreased, and xyloside treatment of cells abrogated the biologic activity of PF4 in a plasma clot culture system. The inhibitory effect of PF4 was retained in a serum-free agar culture system, which indicates that the binding of PF4 to HEL cells induces cell growth inhibition in a direct fashion. Taken together, these findings suggest that PF4 directly acts on HEL cell growth by fixation on heparan sulfate proteoglycans on the HEL cell surface.

Topics: Cell Division; Cell Membrane; Culture Media, Serum-Free; Fibroblast Growth Factor 2; Glycosaminoglycans; Glycosides; Growth Inhibitors; Heparitin Sulfate; Humans; Leukemia, Erythroblastic, Acute; Platelet Factor 4; Polysaccharide-Lyases; Protamines; Tumor Cells, Cultured

Perlecan is a modular heparan sulfate proteoglycan that harbors five domains with homology to the low density lipoprotein receptor, epidermal growth factor, laminin and neural cell adhesion molecule. Using a monoclonal antibody directed against the laminin-like domain of perlecan, we have recently shown that perlecan is widely expressed in all lymphoreticular systems. To investigate further this observation we have studied the expression of perlecan in two human leukemic cell lines. Using reverse transcriptase-PCR, ribonuclease protection assay, and metabolic labeling we detected significant perlecan expression in the multipotential cell line K562, originally derived from a patient with chronic myelogenous leukemia. In contrast, the promyelocytic cell line HL-60 expressed perlecan at barely detectable levels. These results were intriguing because the K562 cells do not assemble or produce a classical basement membrane. Following induction with either sodium butyrate or the phorbol diester 12-0-tetradecanoylphorbol-13-acetate (TPA), K562 and HL-60 differentiate into early progenitor cells with erythroid or megakaryocytic properties, respectively. Following treatment of K562 and HL-60 cells with either of these agents, perlecan expression was markedly increased in K562 cells. In contrast, we could detect perlecan protein synthesis in HL-60 cells only at very low levels, even after induction with TPA or sodium butyrate. Collectively, these results indicate that perlecan is actively synthesized by bone marrow derived cells and suggest that this proteoglycan may play a role in hematopoietic cell differentiation.

Topics: Base Sequence; Butyrates; Butyric Acid; Cell Differentiation; Chondroitinases and Chondroitin Lyases; Glyceraldehyde-3-Phosphate Dehydrogenases; Heparan Sulfate Proteoglycans; Heparitin Sulfate; Humans; Immunoblotting; Leukemia, Erythroblastic, Acute; Leukemia, Promyelocytic, Acute; Molecular Sequence Data; Polysaccharide-Lyases; Proteoglycans; RNA; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured; Up-Regulation

Murine erythroleukemia cells (Friend erythroleukemia cells of a C-10-6 line) synthesized sulfated glycosaminoglycans consisting mainly of heparan sulfate (more than 95%) with a small amount of chondroitin 4-sulfate. The heparan sulfate occurred as proteoglycans, of which the cell-associated component was separated into urea-insoluble (UI) and urea-soluble (US) fractions. The UI proteoglycan consisted of a single homogeneous molecular species with an estimated Mr of 360,000 (C(UI)PG), whereas the US component was composed of two subfractions: a homogeneous species with an Mr of 280,000 (C(US)PGI) and a mixture of compounds with Mr values of less than 80,000 (C(US)PGII), which were isolated in yields of about 110, 340, and 80 micrograms of hexuronate (HexUA), respectively, from 1.37 g of an acetone powder prepared from 5.7 x 10(9) cells in the logarithmic phase of growth. The proteoglycan released into the medium (12 liters) was a single homogeneous species with an Mr of 320,000 (MPG) which was purified in a yield of 500 micrograms of hexuronate. The major, cell-associated proteoglycan, C(US)PGI, had very high contents of serine and glycine, accounting for approximately 80% of the total amino acids. This proteoglycan as well as the other two large proteoglycans, C(UI)PG and MPG, were highly resistant to degradation by various proteinases. These three proteoglycans, C(UI)PG, C(US)PGI, and MPG, had heparan sulfates with estimated Mr values of 32,000, 27,000, and 30,000. On the other hand, the Mr of the smaller proteoglycan, C(UI)PGII, was not significantly different before and after beta-elimination, indicating that it contains only a small peptide, if any. The heparan sulfate of this proteoglycan consisted of smaller and heterogeneous molecular species with Mr values of 26,000, 20,000, and 4,000. Digestion of these heparan sulfates with heparitinase I plus II resulted in almost complete depolymerization and gave six unsaturated disaccharides, delta HexUA-GlcNAc, delta HexUA-Glc-NAc(6-SO4), delta HexUA-GlcNSO3, delta HexUA-GlcNSO3 (6-SO4), delta HexUA(2-SO4)-GlcNSO3, and delta HexUA(2-SO4)-GlcNSO3(6-SO4). The relative amounts of these disaccharides generated from the individual heparan sulfates showed that an average ratio of sulfate residues to repeating disaccharide units of the C(US)PGII-derived heparan sulfate (0.97) was significantly higher than those of the other three large proteoglycan-derived glycosaminoglycans (0.54-0.70).

Topics: Amino Acids; Animals; Chondroitinases and Chondroitin Lyases; Chromatography, Liquid; Electrophoresis, Gel, Two-Dimensional; Heparitin Sulfate; Leukemia, Erythroblastic, Acute; Mice; Proteoglycans; Tumor Cells, Cultured